Advertisement

Familiäres Prostatakarzinom

  • Timm O. Goecke
  • Brigitte Royer-Pokora
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Das Prostatakarzinom gehört zu den am häufigsten diagnostizierten Tumoren. In den letzten Jahren haben sowohl dessen Inzidenz als auch dessen Mortalität zugenommen, dabei finden sich erhebliche ethnische Unterschiede. Eine hohe Inzidenz besteht bei schwarzen und weißen US-Amerikanern, Schweden, Kanadiern, eine niedrige bei Japanern und Chinesen (Hsing et al. 2000). Trotz erheblicher Inzidenzunterschiede weisen Autopsiedaten darauf hin, dass die Prävalenz latenter Prostatatumoren in verschiedenen Populationen nur eine geringe Variation aufweist (Breslow et al. 1977). Als wesentliche Risikofaktoren für das Prostatakarzinom sind bislang lediglich Alter, ethnischer Hintergrund und positive Familienanamnese etabliert. Etwa 10–15% aller Prostatakarzinome treten familiär auf.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlbom A, Lichtenstein P, Malmström H, Feychting M, Hemminki K, Pedersen NL (1997) Cancer in twins; genetic and nongenetic familial risk factors. J Natl Cancer Inst 89:287–293PubMedGoogle Scholar
  2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of man aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980PubMedGoogle Scholar
  3. American Joint Committee on Cancer (1997) Cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia New YorkGoogle Scholar
  4. American Urological Association Prostate Cancer Clinical Guidelines Panel (1997) Report on the management of clinically localized prostate cancer. American Urological Association, Baltimore. In: Vita VT de, Hellman S, Rosenberg SA (eds) Cancer. Principles and praclice of oncology, 5th edn. Lippincott-Raven, Philadelphia New YorkGoogle Scholar
  5. Anderson DE, Badzioch MD (1993) Familial breast cancer risks. Effect of prostate and other cancers. Cancer 72:114–119PubMedGoogle Scholar
  6. Aprikian AG, Zhang Z-F, Fair WR (1994) Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients. Cancer 74:1768–1777PubMedGoogle Scholar
  7. Aprikian AG, Bazinet M, Plante M et al. (1995) Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 154:404–406PubMedGoogle Scholar
  8. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI (1995) Pathological features of hereditary prostate cancer. J Urol 153:987–992PubMedGoogle Scholar
  9. Bauer JJ, Srivastava S, Connelly RR et al. (1998) Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 51:970–976PubMedGoogle Scholar
  10. Berger U, Wilson P, McClelland RA et al. (1988) Immunocytochemical detection of 1,25-difiydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67:607–613PubMedGoogle Scholar
  11. Berry R, Schaid DJ, Smith JR et al. (2000) Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 66:539–546PubMedGoogle Scholar
  12. Berthon P, Valeri A, Cohen-Akenine A et al. (1998) Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62:1416–1424PubMedGoogle Scholar
  13. Bieche I, Khodia A, Lidereau R (1999) Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer 24:255–263PubMedGoogle Scholar
  14. Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075–1107PubMedGoogle Scholar
  15. Bochum S, Haeussler J, Geyer P et al. (2000) Linkage analysis of the HPCX locus on chromosome Xq27-28 in German prostate cancer families. Med Genet 12:128Google Scholar
  16. Bostwick D (1992) Prostatic intraepithelial neoplasia: current concepts. J Cell Biochem [Suppl H] 16:10–19Google Scholar
  17. Bova GS, Isaacs S, Partin A, Isaacs WB, Walsh PC (1995) Biological aggressiveness of hereditary prostate cancer (HPC); long term evaluation following radical prostatectomy. J Urol 153:505AGoogle Scholar
  18. Bova GS, Partin AW, Isaacs SD et al. (1998) Biological aggressiveness of hereditary prostate cancer: long-term evaluationfollowingradical prostatectomy. J Urol 160:660–663PubMedGoogle Scholar
  19. Boyle P, Severi G (1999) Epidemiology of prostate cancer. Eur Urol 35:370–376PubMedGoogle Scholar
  20. Brawer MK (1999) Prostate-specific antigen: current status. CA Cancer J Clin 49:264–281PubMedGoogle Scholar
  21. Bratt O (2000) Hereditary prostate cancer. BJU Int 85:588–598PubMedGoogle Scholar
  22. Bratt O, Kristoffersson U, Lundgren R, Olsson H (1997) The risk of malignant tumors in first-degree relatives of men with early onset prostate cancer: a population-based cohort study. Eur J Cancer 33:2237–2240PubMedGoogle Scholar
  23. Bratt O, Kristoffersson U, Olsson H, Lundgren R (1998) Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 34:19–24PubMedGoogle Scholar
  24. Bratt O, Kristoffersson U, Lundgren R, Olsson H (1999a) Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 35:272–277PubMedGoogle Scholar
  25. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang Q-X, Olsson H (1999b) CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to proslate cancer risk. Br J Cancer 81:672–676PubMedGoogle Scholar
  26. Breslow N, Chan CW, Dhom G et al. (1997) Latent carcinoma of prostate of autopsy in seven areas. Int J Cancer 20:680–688Google Scholar
  27. Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR (1982) Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1:47–69Google Scholar
  28. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367–3371PubMedGoogle Scholar
  29. Carter BS, Bova S, Beaty TH et al. (1993) Hereditary prostate cancer: epidemiologic andclinical features. J Urol 150:797–802PubMedGoogle Scholar
  30. Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837–1842PubMedGoogle Scholar
  31. Chamberlain NL, Driver ED, Miesfeld RL (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect trans activation function. Nucleic Acids Res 22:3181–3186PubMedGoogle Scholar
  32. Chan JM, Stampfer MJ, Giovannucci E et al. (1998) Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279:563–566PubMedGoogle Scholar
  33. Cher ML, Bova GS, Moore DH et al. (1996) Genetic alterations in untreated metastases and androgen-in de pendent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091–3102PubMedGoogle Scholar
  34. Coetzee GH, Ross RK (1994) Prostate cancer and the androgen receptor. J Natl Cancer Inst 86:872–873PubMedGoogle Scholar
  35. Cooney KA, McCarthy JD, Lange E et al. (1997a) Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89:955–959PubMedGoogle Scholar
  36. Cooney KA, Lange E, Lange K (1997b) Letter to the Editor. J Natl Cancer Inst 89:1894Google Scholar
  37. Cooney KA, Tsou HC, Petty EM et al. (1999) Absence of PTEN germ-line mutations in men with potential inherited predisposition to prostate cancer. Clin Cancer Res 5:1387–1391PubMedGoogle Scholar
  38. Corder EH, Guess HA, Hulka BS et al. (1993) Vitamin-D-and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467–472PubMedGoogle Scholar
  39. Correa-Cerro L, Wöhr G, Berthon P et al. (1998) No association of short CAG repeats in the androgen receptor gene with prostate cancer in an European population. Med Genel 10:132Google Scholar
  40. Cunningham JM, Shan A, Wich MJ et al. (1998) Familial prostate cancer and possible associated malignancies: nation-wide register cohort study in Sweden. Int J Cancer 78:293–297Google Scholar
  41. Davis DL, Russell DW (1993) Unusual length polymorphism inhuman steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet 2:820PubMedGoogle Scholar
  42. Dhom G (1981) Pathologie des Prostata-Carcinoms. Verh Dtsch Ges Urol 32:9–16Google Scholar
  43. Dhom G (1991) Pathologie der Prostata. In: Heldinger CE, Dhom G (Hrsg) Pathologie desmännlichen Genitale. Spezielle anatomische Pathologie, Bd 21. Springer, Berlin Heidelberg New YorkGoogle Scholar
  44. Doli JA, Suarez BK, Donis-Keller H (1996) Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromosome 13. Am J Hum Genet 58:425–428Google Scholar
  45. Dunsmuir WD, Edwards SM, Lakhani SR et al. (1998) Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. Br J Cancer 78:1430–1433PubMedGoogle Scholar
  46. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV (1995) Mutation of the MX11 gene in prostate cancer. Nat Genet 9:249–255PubMedGoogle Scholar
  47. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992) Genelic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12:241–253PubMedGoogle Scholar
  48. Edwards SM, Dearnaley DP, Ardern-Jones A et al. (1997) No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. Br J Cancer 76:992–1000PubMedGoogle Scholar
  49. Edwards SM, Dunsmuir WD, Gillett CE et al. (1998) Immunhistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. Int J Cancer 78:1–7PubMedGoogle Scholar
  50. Eeles RA, Durocher F, Edwards S et al. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 62:653–658PubMedGoogle Scholar
  51. Ekman P, Grönberg H, Matsuyama H, Kivineva M, Bergerheim USR, Li C (1999) Links between genetic and environmental factors and prostate cancer risk. Prostate 39:262–268PubMedGoogle Scholar
  52. Elston RC, Buxbaum S, Jacobs KB, Olson JM (2000) Haseman and Elston revisited. Genet Epidemiol 19:1–17PubMedGoogle Scholar
  53. Fincham SM, Hill GB, Hanson J, Wijayasinghe C (1990) Epidemiology of prostatic cancer: a case-control study. Prostate 17:189–206PubMedGoogle Scholar
  54. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedGoogle Scholar
  55. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5:121–126PubMedGoogle Scholar
  56. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV (1997) Diagnostic and prognostic markers for human prostate cancer. Prostate 31:264–281PubMedGoogle Scholar
  57. Ghadirian P, Cadotte M, Lacroix A, Perret C (1991) Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 19:43–52PubMedGoogle Scholar
  58. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P (1997) Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 70:679–681PubMedGoogle Scholar
  59. Gibbs M, Stanford JL, McIndoe RA et al. (1999a) Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64:776–787PubMedGoogle Scholar
  60. Gibbs M, Chakrabarti L, Stanford JL et al. (1999b) Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet 64:1095–1097Google Scholar
  61. Gibbs M, Stanford JL, Jarvik GP et al. (2000) A genomic scan of families with prostate cancer identifies multiple regions of interest. Am I Hum Genet 67:100–109Google Scholar
  62. Giovannucci E (1999) Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res [Suppl 3] 51:34–41PubMedGoogle Scholar
  63. Giovannucci E, Stamper MJ, Krirhivas K et al. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320–3323PubMedGoogle Scholar
  64. Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologie pathology: the prostate. Lea & Febiger, PhiladelphiaGoogle Scholar
  65. Gleason DF, Meilinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMedGoogle Scholar
  66. Glover FE, Coffey DS, Douglas LL et al. (1998) Family study of prostate cancer in Jamaica. Urology 52:441–443PubMedGoogle Scholar
  67. Goldgar DE, baston DF, Cannon-Albright I.A, Skolnick MH (1994) Systemic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600–1608PubMedGoogle Scholar
  68. Goode EL, Stanford JL, Chakrabarti L et al. (2000) Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol 18:251–275PubMedGoogle Scholar
  69. Grönberg H, Damber L, Damber J-L (1994a) Studies of genetic factors in prostate cancer in a twin population. J Urol 152:1484–1489PubMedGoogle Scholar
  70. Grönberg H, Damber JE, Jonsson H, Lenner P (1994b) Patient age as a prognostic factor in prostate cancer. J Urol 152:892–895PubMedGoogle Scholar
  71. Grönberg H, Damber L, Damber J-L (1996) Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 77:138–143PubMedGoogle Scholar
  72. Grönberg H, Damber L, Damber J-E, Iselius L (1997a) Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 146:552–557PubMedGoogle Scholar
  73. Grönberg H, Xu J, Smith JR et al. (1997b) Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 57:4707–4709PubMedGoogle Scholar
  74. Grönberg H, Isaacs SD, Smith JR et al. (1997c) Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 278:1251–1255PubMedGoogle Scholar
  75. Grönberg H, Damber L, Tavelin B, Damber J-E (1998) No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 82:564–567PubMedGoogle Scholar
  76. Grönberg H, Smith J, Emanuelsson M et al. (1999a) In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet 65:134–140PubMedGoogle Scholar
  77. Grönberg H, Wiklund F, Damber J-E (1999b) Age specific risks of familial prostate carcinoma. A basis for screening recommendations inhigh risk populations. Cancer 86:477–483PubMedGoogle Scholar
  78. Guo S-W (1998) Inflation of sibling recur rene e-risk ratio, due to ascertainment bias and/or overreporting. Am J Hum Genet 63:252–258PubMedGoogle Scholar
  79. Häggman MJ, Macoska JA, Wojno KJ, Oesterling JE (1997) The relationship between prostatic intraepithelial neoplasia and prostate cancer. Critical issues. J Urol 158:12–22PubMedGoogle Scholar
  80. Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate mortality. Cancer 70:2861–2869PubMedGoogle Scholar
  81. Hanlon AL, Hanks GE (1998) Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 52:735–738PubMedGoogle Scholar
  82. Hanus MC, Zagars GK, Pollack A (1999) Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 43:379–383PubMedGoogle Scholar
  83. Harrela M, Koistinen H, Kaprio J et al. (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1. and IGFBP-3. J Clin Invest 98:2612–2615PubMedGoogle Scholar
  84. Harris EI. (1997) Importance of heritable and nonheritable variation in cancer susceptibility: evidence from a twin study. J Natl Cancer Inst 89:270–272PubMedGoogle Scholar
  85. Hayes RB, Liff JM, Pottern LM et al. (1995) Prostate cancer risk in US blacks and whites with a family history of cancer. Int J Cancer 60:361–364PubMedGoogle Scholar
  86. Heimdal K, Olsson H, Tretli S, Flodgren P, Barresen AL, Fossa SD (1996) Risk of cancer in relatives of testicular cancer patients. Br J Cancer 73:970–973PubMedGoogle Scholar
  87. Hoüoway SM, Sofaer JA (1992) Coefficients of relationship by isonymy among registrations for five common cancers in Scottish males. J Epidemiol Community Health 46:368–372Google Scholar
  88. Honda GD, Bernstein L, Ross RK, Greenland S, Gerkins V, Henderson BE (1988) Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. Br J Cancer 57:326–331PubMedGoogle Scholar
  89. Hsieh C-L, Oakley-Girvan I, Gallagher RP et al. (1997) Utter to the Editor. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89:1893–1894PubMedGoogle Scholar
  90. Hsing AW, Tsao L, Devesa SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60–67PubMedGoogle Scholar
  91. Hubert A, Peretz T, Manor O et al. (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostrate cancer. Am J Hum Genet 65:921–924PubMedGoogle Scholar
  92. Ingles SA, Ross RK, Yu MC et al. (1997) Association of prostate cancer risk with vitamin D receptor and androgen receptor polymorphisms. J Natl Cancer Inst 89:166–170PubMedGoogle Scholar
  93. Ingles SA, Coetzee GA, Ross RK et al. (1998) Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 58:1620–1623PubMedGoogle Scholar
  94. Irvine RA, Yu MC, Ross RK, Coetzee GA (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937–1940PubMedGoogle Scholar
  95. Isaacs SD, Kiemeney LALM, Baffoe-Bonnie A, Beaty TH, Walsh PC (1995) Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 87:991–996PubMedGoogle Scholar
  96. Jacobsen SJ, Katusic SK, Bergstralh EJ et al. (1995) Incidence of prostate cancer diagnosis in the eras before and after serum pro state-specific antigen testing. JAMA 274:1445–1449PubMedGoogle Scholar
  97. Jarvik GP (1998) Complex segregation analyses: uses and limitations. Am J Hum Genet 63:942–946PubMedGoogle Scholar
  98. Jenster G (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26:407–421PubMedGoogle Scholar
  99. Jewett HJ (1975) The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2:105–124PubMedGoogle Scholar
  100. Jishi MF, Itnyre JH, Oakley-Girvan IA, Piver MS, Whittemore AS (1995) Risks of cancer among members of families in the Gildna Radner Familial Ovarian Cancer Registry. Cancer 76:1416–1421PubMedGoogle Scholar
  101. Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35:1248–1257PubMedGoogle Scholar
  102. Juul A, Bang P, Hertel NT et al. (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size,and body mass index. J Clin Endocrinol Metab 78:744–752PubMedGoogle Scholar
  103. Juul A, Dalgaard P, Blum WF et al. (1995) Serum levels of insulin-likegrowthfactor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80:2534–2542PubMedGoogle Scholar
  104. Kaghad M, Bonnet H, Yang A et al. (1997) Mo no allelic ally expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819PubMedGoogle Scholar
  105. Keetch DW, Rice JP, Suarez BK, Catalona WJ (1995) Familial aspects of prostate cancer: a case-control study. J Urol 154:2100–2102PubMedGoogle Scholar
  106. Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ (1996) Clinical and pathological features of hereditary prostate cancer. J Urol 155:1841–1843PubMedGoogle Scholar
  107. Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146:244–248PubMedGoogle Scholar
  108. Kibel AS, Isaacs SD, Isaacs WB, Bova GS (1998) Vitamin D receptor polymorphisms and lethal prostale cancer. J Urol 160:1405–1409PubMedGoogle Scholar
  109. Knudson A (1971) Statistical study of retinoblastoma. Proc Nad Acad Sci USA 68:820–823Google Scholar
  110. Kolonel LN, Yoshizawa CN, Hankin JH(1988) Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127:999–1012PubMedGoogle Scholar
  111. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK (eds) (1995) SEER cancer statistics review, 1973-1992: tables and graphs, National Cancer Institute. NIH Pub. 96-2789, BethesdaGoogle Scholar
  112. Krain LS (1974) Some epidemiologic variables in prostatic carcinoma in California. Prev Med 4:59–159Google Scholar
  113. Kramer BS, Gohagan JK, Prorok PC (1997) Is screening for prostate cancer the current gold standard? — “No”. Eur J Cancer 33:348–353PubMedGoogle Scholar
  114. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 58:1347–1363PubMedGoogle Scholar
  115. Kuczyk MA, Serth J, Bokemeyer C et al. (1998) The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol Rep 5:213–216PubMedGoogle Scholar
  116. Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997a) Familial prostate cancer: a different disease? J Urol 158:2197–2201PubMedGoogle Scholar
  117. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA (1997b) Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 15:1478–1480PubMedGoogle Scholar
  118. Kupelian PA, Klein EA, Witte JS (1999) Letter to the Editor. J Urol 161:1585–1586PubMedGoogle Scholar
  119. Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241–247PubMedGoogle Scholar
  120. Lange EM, Chen H, Brierley K et al. (1999) Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 5:4013–4020PubMedGoogle Scholar
  121. Laniado ME (1998) Letter to the Editor. Prostate cancer potentially linked to the HPC1 gene. JAMA 279:507PubMedGoogle Scholar
  122. Latil A, Cussenot O, Fournier G, Baron C, Lidereau R (1995) Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1:1385–1389PubMedGoogle Scholar
  123. Latil A, Cussenot O, Fournier G, Lidereau R (1997) Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours. Int J Cancer 71:118Google Scholar
  124. Lesko SM, Rosenberg L, Shapiro S (1996) Family history and prostate cancer risk. Am J Epidemiol 144:1041–1047PubMedGoogle Scholar
  125. Liaw D, Marsh DJ, Li J et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64–67PubMedGoogle Scholar
  126. Lu J, Danielsen D (1996) Short report on DNA marker at candidate locus: a StuI polymorphism in the human androgen receptor gene. Clin Genet 49:323–324PubMedGoogle Scholar
  127. Lyn D, Cherney BW, Lalande M et al. (1993) A duplicated region is responsible for the poly (ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer. Am J Hum Genet 52:124–134PubMedGoogle Scholar
  128. Ma J, Stampfer MJ, Gann PH et al. (1998) Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7:385–390PubMedGoogle Scholar
  129. Makridakis N, Ross RK, Pike MC et al. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5o-reductase. Cancer Res 57:1020–1022PubMedGoogle Scholar
  130. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami H-O (1997) Insulin-like growth factor 1 in relation to prostate cancer and benigne prostatic hyperplasia. Br J Cancer 75:1115–1118Google Scholar
  131. Matikainen MP, Schleutker J, Mörsky P, Kallionemi O-P, Tammela TLJ (1999) Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 5:1275–1279PubMedGoogle Scholar
  132. McIndoe RM, Stanford JL, Gibbs M et al. (1997) Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 61:347–353PubMedGoogle Scholar
  133. McWhorter WP, Hernandez AD, Meikle W et al. (1992) A screening study of prostate cancer in high risk families. J Urol 148:826–828PubMedGoogle Scholar
  134. Meikle AW, Smith JA, West DW (1985) Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 6:121–128PubMedGoogle Scholar
  135. Meikle AW, Stephenson RA, Lewis CM, Wiebke GA, Middleton RG (1997) Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostateand benigne prostatic hyperplasia in twins. Prostate 33:105–111PubMedGoogle Scholar
  136. Mcttlin C, Natarajan N, Huben R, Raghavan D (1995) Reported family history of cancer in 1271 prostate cancer cases and 1909 controls. Urol Oncol 1:240–245Google Scholar
  137. Miller K, Weißbach L (eds) (1999) Leitlinien zur Diagnostik von Prostatakarzinomen. Urologe A 38:389–401Google Scholar
  138. Miller K, Weißbach L (eds) (1999) Leitlinien zur Therapie von Prostatakarzinomen. Urologe A 38:630–639Google Scholar
  139. Mishina T, Watanabe H, Araki H, Nakao M (1985) Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 6:423–436PubMedGoogle Scholar
  140. Monroe KR, Yu MC, Kolonel LN et al. (1995) Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1:827–829PubMedGoogle Scholar
  141. Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lovati G (1956) Recherches clinico-statistiques et génétiques sur les neoplasies de la prostate. Acta Genet 6:304–305PubMedGoogle Scholar
  142. Morrison NA, Qi JC, Tokita A et al. (1994) Prediction of bone density from vitamin D receptor allels. Nature 367:284–287PubMedGoogle Scholar
  143. Narod SA (1998) Genetic epidemiology of prostate cancer. Biochim Biophys Acta 1423:F1–F13Google Scholar
  144. Narod SA, Dupont A, Cusan L et al. (1995) The impact of family history on early detection of prostate cancer. Nat Med 1:99–101PubMedGoogle Scholar
  145. Nastiuk KL, Mansukhani M, Terry MB et al. (1999) Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40:172–177PubMedGoogle Scholar
  146. Neuhausen SL, Farnham JM, Kort E, Tavtigian SV, Skolnick MH, Cannon-Albright LA (1999) Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet 8:2437–2442PubMedGoogle Scholar
  147. Nomura AMY, Kolonel LN (1991) Prostate cancer: a current perspective. Epidemiol Rev 13:200–227PubMedGoogle Scholar
  148. Norrish AE, McRae CU, Cohen RJ, Jackson RT (1999) A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 84:311–315PubMedGoogle Scholar
  149. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849PubMedGoogle Scholar
  150. Ohtake N, Hatori M, Yamanaka H, Nakata S, Sada M, Tsuji T (1998) Familial prostate cancer in Japan. Int J Urol 5:138–145PubMedGoogle Scholar
  151. Olsen JH, Seersholm N, Boice JD, Krüger Kjaer S, Fraumeni JF (L999) Cancer risks in close relatives of women with early-onset breast cancer — a population-based incidence study. Br J Cancer 79:673–679Google Scholar
  152. Olsson H, Andersson H, Johansson O, Möller TR, Kristoffersson U, Wenngren E (1993) Population-based cohort investigations of the risk of malignant tumors in first-degree relatives and wives of men with breast cancer. Cancer 71:1273–1278PubMedGoogle Scholar
  153. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P (1997) Heredity and prostate cancer: a study of world war II veteran twins. Prostate 33:240–245PubMedGoogle Scholar
  154. Paris PL, Witte S, Kupelian PA et al. (2000) Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res 60:3645–3649PubMedGoogle Scholar
  155. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548–552PubMedGoogle Scholar
  156. Rader JS, Neuman RJ, Brady J et aL (1998) Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. Obstet Gynecol 92:589–595PubMedGoogle Scholar
  157. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK (1995) Genetic variability of the human SDR5A2 gene: implications for prostate cancer risk. Cancer Res 55:3973–3975PubMedGoogle Scholar
  158. Ross RK, Bernstein L, Lobo RA et aL (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887–889PubMedGoogle Scholar
  159. Ross RK, Coetzee GA, Pearce CL et al. (1999) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Eur Urol 35:355–361PubMedGoogle Scholar
  160. Sasco AJ, Lowenfels AB, Pasker-dejong P (1993) Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53:538–549PubMedGoogle Scholar
  161. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN (1998) Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62:1425–1438PubMedGoogle Scholar
  162. Schleutker J, Matikainen M, Smith JR et al. (1997) Search for founder effects: a genetic and epidemiologic study of hereditary prostate cancer in Finland, Am J Hum Genet [Suppl] 6LA293Google Scholar
  163. Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R (1977) Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep 61:181–186PubMedGoogle Scholar
  164. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostale cancer? Anticancer Res 10:1307–1311PubMedGoogle Scholar
  165. Sellers TA, Potter JD, Rich SS et al. (1994) Familial clustering of breast and prostate cancer and risk of menopausal breast cancer. J Natl Cancer Inst 86:1860–1865PubMedGoogle Scholar
  166. Shibata A, Whittemore AS (1997) Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate 32:65–72PubMedGoogle Scholar
  167. Shimizu H, Ross RK, Bernstein L (1991) Passible underestimation of the incidence tate of prostate cancer in Japan. Jpn J Cancer Res 82:483–485PubMedGoogle Scholar
  168. Sigurdsson S, Thorlacius S, Tomasson J et al. (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75:758–761PubMedGoogle Scholar
  169. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ (2000) BRCA1 and BRCA2 have little role in familial prostate cancer. Cancer Res 60:1371–1375PubMedGoogle Scholar
  170. Slattery ML, Kerber LA (1994) Family history of cancer and colon cancer risk: the Utah population database. J Natl Cancer Inst 86:1618–1626PubMedGoogle Scholar
  171. Smith JR, Freije D, Carpten JD et al. (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371–1374PubMedGoogle Scholar
  172. Spaas PG, Bagshaw MA (1990) Prostate cancer occurring in identical twins: a case report. Prostate 16:219–223PubMedGoogle Scholar
  173. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR (1991) Familial patterns of prostate cancer: a case-control analysis. J Urol 146:1305–1307PubMedGoogle Scholar
  174. Stanford JL, Just JJ, Gibbs M et aL (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57:1194–1198PubMedGoogle Scholar
  175. Stanford JL, Stephenson RA, Coyle LM et al. (1999) Prostate cancer trends 1973-1995, SEER Program, National Cancer Institute. NIH Pub. No. 99-4543, BethesdaGoogle Scholar
  176. Stanford JL, Feng Z, Hamilton AS et al. (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. The Prostate Cancer Outcofnes Study. JAMA 283:354–360PubMedGoogle Scholar
  177. Steele R, Lees REM, Kraus AS, Rao C (1971) Sexual factors in the epidemiology of cancer of the prostate. J Chronic Dis 24:29–37PubMedGoogle Scholar
  178. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17:337–347PubMedGoogle Scholar
  179. Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedGoogle Scholar
  180. Suarez BK, Lin J, Burmester JK et al. (2000) A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 66:933–944PubMedGoogle Scholar
  181. Sun S, Narod SA, Aprikian A, Ghadirian P, Iabrie F (1995) Androgen receptor and familial prostate cancer. Nat Med 1:848–849PubMedGoogle Scholar
  182. Taylor JA, Hirvonen A, Watson M, Pittman G, Möhler JL, Bell DA (1996) Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56:4108–4110PubMedGoogle Scholar
  183. Teare MD, Wallace SA, Harris M, Howell A, Birch JM (1994) Cancer experience in relatives of an unselected series of breast cancer patients. Br J Cancer 70:102–111PubMedGoogle Scholar
  184. Thibodeau SN, Wang Z, Tester DJ et al. (1997) Linkage analysis at the HPC1 locus in hereditary prostate cancer families. Am J Hum Genet [Suppl] 6LA297Google Scholar
  185. Thiessen EU (1974) Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 34:1102–1107PubMedGoogle Scholar
  186. Thorlacius S, Olafsdottir G, Tryggvadottir I. et al. (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117–119PubMedGoogle Scholar
  187. Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch H, Narod SA (1995) A large multisite cancer family is linked to BRCA2. J Med Genet 32:982–984PubMedGoogle Scholar
  188. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 305:855–857PubMedGoogle Scholar
  189. Von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N (1997) American Cancer Society guidelines for the early detection of prostate cancer. Cancer 80:1805-1807Google Scholar
  190. Walther MM (1998) Letter to the Editor. Prostate cancer potentially linked to the HPC1 gene. JAMA 279:507–508PubMedGoogle Scholar
  191. Waterbor JW, Bueschen AJ (1995) Prostate cancer screening (United States). Cancer Causes Control 6:267–274PubMedGoogle Scholar
  192. Whit more WF (1984) Natural history and staging of prostate cancer. Urol Clin North Am 11:205–220Google Scholar
  193. Whittemore AS, Wu AH, Kolonel LN et al. (1995) Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141:732–740PubMedGoogle Scholar
  194. Whittemore AS, Lin IG, Oakley-Girvan I et al. (1999) No evidence of linkage for chromosome 1q42.2-43 in prostate cancer. Am J Hum Genet 65:254–256PubMedGoogle Scholar
  195. Witte JS, Goddard KAB, Conti DV et al. (2000) Genomwide scan for prostate cane er-aggressiven ess loci. Am J Hum Genet 67:92–99PubMedGoogle Scholar
  196. Wilkens EP, Freije D, Xu J et al. (1999) No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 39:280–284PubMedGoogle Scholar
  197. Wölk A, Mantzoros CS, Andersson S-O et al. (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based case-control study. J Natl Cancer Inst 90:911–915PubMedGoogle Scholar
  198. Woolf CM (1960) An investigation of the familial aspects of carcinoma of the prostate. Cancer 13:739–744PubMedGoogle Scholar
  199. Wu AH, Whittemore AS, Kolonel LN et al. (1995) Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarker Prev 4:735–741Google Scholar
  200. Xu J, Meyers D, Freija D et al. (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20:175–179PubMedGoogle Scholar
  201. Xu J and the International Consortium for Prostate Cancer Genetics (2000) Combined analysts of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 66:945–957PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Timm O. Goecke
    • 1
  • Brigitte Royer-Pokora
    • 1
  1. 1.Heinrich-Heine-Universität Medizinische EinrichtungenInstitut für Humangenetik und AnthropologieDüsseldorf

Personalised recommendations